title: Authors' reply.
authors.affiliation: Mark Taylor, Royal Edinburgh Hospital, Edinburgh, UK, and University of Queensland, Brisbane, Australia. Email: marktaylor2@nhs.net; Udayanga Perera, District General Hospital, Monaragala, Sri Lanka.
authors.forename: Mark
authors.initials: M
authors.lastname: Taylor
authors.affiliation: Mark Taylor, Royal Edinburgh Hospital, Edinburgh, UK, and University of Queensland, Brisbane, Australia. Email: marktaylor2@nhs.net; Udayanga Perera, District General Hospital, Monaragala, Sri Lanka.
authors.forename: Udayanga
authors.initials: U
authors.lastname: Perera
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D015928:Cognitive Behavioral Therapy / Q000379:methods*; D006801:Humans; D017410:Practice Guidelines as Topic / Q000592:standards*; D011618:Psychotic Disorders / Q000628:therapy*; D012559:Schizophrenia / Q000628:therapy*
chemical_list: D014150:Antipsychotic Agents